INTRODUCTION
microRNAs (miRNAs) are recently discovered new regulatory class of short noncoding single-stranded RNAs of approximately 18 -24 nucleotides (nt), they regulate post-transcriptional gene expression by imperfect base paring with complementary sequences location mainly, but not exclusively, in the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs) (1) . microRNAs represent one of the major regulatory family of genes in eukaryotic cells that inhibit the expression of mRNAs by translation repression or/and destabilizing target transcript (2) . microRNA alterations are involved in the initiation and progression of human cancer. The microRNA genes can function as oncogenes (miRNA-17-92, miRNA 155/BIC) or tumor suppressor genes (miR-15a/mir-16, and miR-143/miR-145). Frank Slack called miRNAs, which play role in causing cancer, The combination of genetic or epigenetic events could contribute to the downregulation or overexpression of miRNAs (3) . In the last three years, significant deregulation of miRNA expression in many human cancer and lymphomas was demonstrated. Translocation breakpoints, the inactivation of tumor suppressor genes, and abnormalities in the apoptotic pathways are associated with many types of lymphomas (4) . Calin A et al., 2004 suggested that one or more tumor suppressing genes are involved in pathogenesis of B cell lymphomas. The application of microarray mir technology led to the discovery of miRNA genes expression signature for the major groups of non-Hodgkin's lymphoma. microRNA expression profiles could correlate with particular tumor phenotypes and can be used as a very accurate diagnostic tool for classification and prognosis of cancer or lymphoma (5) . The expression profiles of microRNAs in CLL may be useful as prognostic signature or may predict outcome of disease on therapy (6) . Nowadays, several research groups explored the potential of microRNA-based cancer therapy with antagomir that inhibits specific microRNAs (6, 7) . The molecular classification of non-Hodgkin's lymphoma using miRNA microarray profiling is area of intense research. In this review, we summarize the recent advances on miRNA genes: their identification, biogenesis, function, and expression profiling in non-Hodgkin's lymphoma.
A BRIEF HISTORY OF microRNA DISCOVERY
The history of the miRNAs discovery is an interesting story. Alexander Rich of RNA may be a part of the control apparatus for on or off the synthesis of the proteins. One might imagine that one RNA strand is continually used in protein synthesis, while the other strand is used to control the rate at which with genetic studies at cell lineages and in C. elegans. Sydney Brevaer from Cambridge, middle 1970, discovered first heterochronous genes Lin-4 mutant in C. elegans. Later, Howard Robert Horvitz identified another mutant Lin-14 gene. The Ambros Victor group from MIT, 1993, identified the first known control of post embryonic development changes in C. elegans, but the structure and limits of this gene were unknown at that time (9) . At the same time, Gary Ruwkin discovered Lin-14 as first microRNA target gene (10) . These two discoveries made by Ambros and Ruwkin groups (June 1992), showed a novel posttranscriptional mechanism in which Lin-4 negatively regulates Lin-14 translation by binding directly to its 3' UTR (11) . After 7 years from discovery of Lin-4, Ruwkin group identified and cloned second microRNA, , that encodes a small RNA, which negatively regulates gene Lin-41. The Let-7 and Lin-41 and hbl-1 are evolutionary conserved in various organisms that Lin-4 negatively regulates Lin-14 and Lin-28, and Lin-14 negatively regulates Lin-28, Lin-29. Lin-29 acivates larval-to-adult (L A) switch (13) . In Ambros laboratory, Eric Moss (1997) showed that Lin-4 regulates Lin-28 by a 3' UTR element and that Lin-4 regulates more than one mRNA (14) . In that way, central genetic dogma (Figure 1 ) was completed by discovering of posttranscriptional activity of microRNAs on mRNAs. The rapid progression of research in microRNA area discovered more than 5000 of microRNAs in different prokaryotic and eukaryotic organisms. The microRNAs are discovered in Epstein-Barr virus, cytomegalo virus, Kaposi sarcoma herpes virus, SV-40, and HIV-1 virus. In molecular researching of microRNA (from 1999 to 2001), exogenous dsRNA is identified by Dicer enzymes and conversion in mature miRNA molecules, and demonstrated miRNP complex by Nothern blot analysis (15 In 2006, Nobel Prize for physiology and medicine was awarded to Andrew Z Fire and Crony C Mello for discovery of RNA interference gene silencing by double-strand RNA (dsRNA) (16) . In diverse organisms, microRNAs play roles in many processes from cell proliferation, apoptosis to hematopoiesis and cancer. The microRNA can function as a novel biomarker for disease diagnosis and is a new strategy for antagomir therapy (15, 17) .
BIOGENESIS AND FUNCTION OF microRNAS
Human miRNA genes are located in all chromosomes except Y chromosome and they are nonrandomly distributed in the genome. About 50% miRNAs are found in clusters and they are transcribed as polycistronic primary transcripts. Cluster mostly contains two or three genes. The largest cluster is composed of seven genes (18) . Approximately 70% of mammalian miRNA genes are located in introns or exons. The 30% of miRNA gene are located in intergenic region and form independent transcription unit (TU) (19) . For some human genes, more than one of microRNAs may be involved in their regulation. More than 80% of conserved miRNAs are tissue specific. Overall 50% of miRNA genes are in cancer-associated genomic regions or in fragile sites. Fragile sites are preferential sites of translocation, deletion, amplification, sister chromatid exchange (SCE), and tumor associated viruses (e.g. HPV, EBV, CMV). Current estimates are that microRNAs genes represent about 1-5% of the predicted genes in humans and they control expression about 20-30% of human protein coding genes. They are involved in crucial biological processes, including the regulation of gene expression, cell proliferation and apoptosis, development, stress resistance, oncogenesis, renewal stem cells, fat metabolism and progression of many diseases (20) . Today, in human genome more than 500 miRNAs have discovered (The miRBase server version 11 contiions 678 humna pre-miR and 847 mature miRNAs) (miRBase: http://www.sanger. ac.uk) but the estimated number of miRNAs genes is as high as 1000 (21) . The biogenesis of miRNAs begins with the transcription of miRNA genes by RNA polymerase II (Pol II) in the nucleus to generate large primary primiRNA transcripts, which are capped (MGpppG) and polyadenylated (AAAAA) (Figure 2 ). Regions of pri-miRNAs have short, imperfectly base-paired stem-loop structures containing sequences that will become the miRNA. These pri-miRNA transcripts processing begins with nuclear cleavage by the microprocessor complex, in which RNase III enzyme Drosha and its co-factor, Pasha or DGCR8 (Di George Syndrome Critical Region Gene 8), release the-70-nucleotide pre-miRNA precursor product with an imperfect RNA duplex structure (22) . The pre-miRNAs are transported from nucleus to cytoplasm by Exportin-5 in a Ran-GTP manner and they form a nuclear heterotrimer. In addition, Exp-5 is important for stabilizing pre-microRNAs in the nucleus. However, in conversion pri-miRNA into pre-miRNA act RNA helicases hnRNPA1, p68, and p72 (23) . In the cytoplasm, another RNase III enzyme, Dicer, generating a transient 22 nucleotide miRNA:miRNA*duplex or hybrids. This duplex is loaded into the miRNA-associated multiprotein RNAinduced silencing complex (miRISC), which includes the Argonaute (Ago) proteins, VIG, Fragile X-related protein, nuclease tudor SN, and various helicases (gemin 3 and gemin 4), and the mature single-stranded miRNA (24) . Ago-2 protein is specifically responsible for RISC cleavage activity. Human Ago-2 protein possesses three residues (D597, D669 and H807), which have the catalytic function (25) . The Ago-2 protein participates in the production of a new class small RNAs, Piwi-interacting RNAs. The Ago-2 binds ssRNA via their PAZ domains, which may have implications for prediction of miRNA targets. Argonaut 2 releases miRNA* and the remaining complex contains the mature miRNA. The mature miRNA then binds to complementary sites in the 3'-untraslated region of a targeted mRNA and negatively regulates gene expression. In case of base pairing between the miRNA and its target, Argonaut 2 cleaves the mRNA, leading to its destruction. The miRNAs that bind to mRNA target with imperfect complementarity block target gene expression at the level of protein translation or cause instability of the mRNA. A reduction or elimination of mature miRNA that functions as a tumor suppressor leads to tumor formation. The amplification or overexpression of miRNA that function as an oncogne also results in tumor formation (15, (18) (19) (20) (21) 26) . The miRNAs act as gene regulators, which mediate through translation repression or mRNA degradation via binding of miRNAsd to sites in the 3'-UTR of proteincoding transcripts. Translation repression interaction depends on perfect base pairing between the seed region end of the miRNA and target site. Six nucleotide are crucial in binding to the target mRNAs and can be predicted by searching for conserved matches to the seed region. microRNAs can inhibit transition initiation, specifically the function of the cap binding initiation factor eIF4E (27, 28) . The function of human miRNAs is largely unknown. However, many studies demonstrated important roles for miRNAs in animal development. miRNA target predictions suggest important roles for miRNAs in humans. In humans, at least 10% of the protein-coding mRNA might be conserved targets of miRNAs. Many miRNAs regulate others human genes that are involved in transcriptional regulation crucial for cellular functions, such as proliferation, apoptosis, or tumorgenesis. The genomic amplification or deletion is a major mechanism of activation of the oncogenic function of miRNA or inactivation of this tumor suppressor function (28, 29) . 
METHODS FOR DETECTION AND ANALYSIS microRNAs
Nowadays, for profiling expression of miRNAs and their quantification to apply in practice several methodologies which include: Northern blot, Dot blot, cloning, RNase protection assay, real-time RT-PCR, oligonucleotide microarrays, LNA modified oligonucleotide probes, in situ detection, single molecule detection, array-based Klenow enzyme assay, and based-based hybridization by flow cytometric assay (29, 30) . Northern blot method is used in the quantification of miRNAs, but is relatively insensitive in measuring miRNA. The realtime RT-PCR method use a stem-loop reverse transcription primer to generate cDNA templates, which are then amplified using specific primers and detected with specific probes, similar to the standard RT-PCR. The most widely used method is based on microarrays. microRNA arrays are now applied to explore the biogenesis of miRNAs, molecular disease characterization, mechanisms of action miRNA and cancerogenesis, in evaluation of drug efficacy and toxicity, and stem cell development, etc. (31, 32) . Recently developed microarrays detect mature miRNA by employing antisense oligonucleotides that specifically bind to the mature miRNA sequences. The microarrays assays are well suited for large scale screening and are very sensitive. However, the use of locked nucleic acid (LNA) modified capture probes (miChip) has improved the ability of miRNA microarrays to measure more accurately levels of highly homologous miRNAs and dramatically reduces the time necessary for carrying out the protocol. The array-based Klenow enzyme assay (RAKE) used to profile miRNA expression from formalin-fixed tissues samples for advancing miRNA research. The most recent innovation in miRNA detection surrounds the based-based flow cytometric method (30, (32) (33) (34) (35) .
microRNAs IN LYMPHOCYTIC DEVELOPMENT
The lymphocytic system offers an ideal model for studying of miRNA in lymphocytic maturation. miRNAs control differentiation of regulatory T-helper cells and the germinal center reaction in T cells dependent antibody response (36) . microRNAs have important role in regulation of normal lymphocyte and lymphoma development. In complex network regulation, function of microRNAs is largely unknown, but its function through transcription factors has been understood to a certain degree (37) . The activity of several microRNAs has been described in lymphopoiesis so far, for example micro-181a -155, 150 ( Figure 3 ). microRNA-181a is highly expressed in thymus and other hematopoietic tissue, and in brain and lung. miR-181a is downregulated in CD4+ lymphocytes and other tissues and inhibits production of CD8+ lymphocytes. miR142s inhibits production of CD4+ and CD8+ T lymphocytes and does not affect B lymphocytes production (38) . In this differentiation, miR-181a acts to target Bcl-2, CD69, and TCR . In addition, Mir-181a in Dicer deficient mice causes downregulation of BCl-2 expression (39). Ablation of Dicer and loss of mature miRNAs in embryonic fibroblast upregulate p19 ARF and p53 levels and cause inhibition cell proliferation. When miR-181a is ectopically expressed in hematopoietic progenitor cells, it regulates B and T lymphocytes development (40) . miR-181a is promoter or positive regulator of B lymphocyte differentiation through the repression of Notch signal pathway, but it can also modulate TCR sensitivity and signaling strength (41) . Mir-181a causes high expression of CD4+CD8+ in double positive (DP) stage of T lymphocyte development, and lower expression of CD4+CD8+ in the mature Th1 and Th2 cells that are only reactive to relatively high affinity for foreign antigens. In T cells differentiation, microRNA-181a increases sensitivity of mature T lymphocytes to antigens by modulation of expression of costimulating molecules CD28 and CTLA-4 (41, 42) . Downregulation of miR-181a in immature T lymphocytes reduces their sensitivity and impaired T cell selection, through downregulation of phosphatases genes (SHP2, PTNP22, DUSP5, DUSP6) (40, 42, 43) . The antagomir may, by inhibition of miR-181a in double positive T lymphocytes, to impair sensitivity to antigens and to inhibit positive and negative selection in the stages T lymphocyte development (42) (43) (44) .
Figure 3. microRNAs and its role in lymphocytic development
The BIC/miR-155 plays a key role in regulation of cytokine, chemokines, and transcription factor genes, which control effector function of the immune system and hemostasis function (45) . The BIC/miR-155 expression is increased in activated B and T lymphocytes, macrophages, and dendritic cells (43, 46, 47) . The miR-155 is critical for B cells maturation and immunoglobulin production in response to antigen. The miR-155 upregulates BCR and TCR and plays role in germinal center formation. The BCR activation results in the induction of c-fos, FOS-B, and JUN-B through ERK (extracellular signaling regulated kinase), and JNK(c-JUN N terminal kinase) pathways. In the miR-155 deficient mice, immunization with antigens causes downregulation of IgG1 response; production of IL-2 and INFgama is reduced and dendritic cells are unable to stimulate T-cell proliferation. The antigens activate follicular B cells and reduce extrafollicular and germinal center responses. About 60 genes participating in B lymphocyte differentiation has been identified so far. However, PU.1 is a direct target gene for miR-155. miR-155 is responsible for normal production of high affinity antibodies and memory response and for activation of cytidine deaminase (AID) gene (48) . In the BIC-miR-155 CD4+ deficient cells, a wide spectrum of miR-155 regulated genes is identified including genes for cytokine, chemokine, and transcription factors (47, 48 
microRNA IN LYMPHOMAGENESIS
The They identified that transgenic mice developed pre-B cell proliferation in spleen and bone marrow and eventually developed frank high grade B cell lymphoma after 6 months (65). BIC might function as a pri-microRNA; it is locked in the nucleus where it is processed into pre-microRNA. The nuclear localization of BIC transcripts is low in normal lymphoid tissue, but elevated in Hodgkin's lymphoma, primary mediastinal lymphomas, and DLBCL. Overexpression of miR-155 was detected in Burkitt lymphomas and post-transplantation lymphoproliferative disease when associated with EBV latency type III infection (66) . In transgenic mice miR-155 may induce polyclonal B cell proliferation. Overexpression of miR-155 in mouse hematopoietic stem cells causes myeloproliferative disease. microRNA-155 BIC acts on the transcriptional factors PU.1 and C EBP , which control B cell differentiation (67) . Another miRNA oncogene is miR-17-92 cluster or Oncomir-1 located at 13q32-33 in intron 3, which is amplified in human B cell lymphomas, lymphoma cell lines, lung cancer, and induced T lymphoma. (Figure 5 ) In experimental B-cell model, miR-17-92 cluster together with c-myc oncogene cooperates in induction of lymphoma progression and apoptosis inhibition (68) . The miR-17-92 cluster induces overexpression of c-myc, and it is a target for c-myc. Transcriptional factor E2F1 is a target for miR-17-92 cluster. This feedback mechanism may help prevent accumulation of excessive amounts of E2F1. c-myc initiates apoptotic tumor-suppressive response, while E2F1 induces p21 protein resulting in S phase arrest of cell cycle (Figures 5,6 ). The complex cyclin D1/miR-17/20 function as regulatory feedback loop. cyclin D1 induces miR-17-5p/miR-20a that limits the proliferative function cyclin D1. miR-17-92 regulates the CDKN1B; hasa-miR-17-5p regulates E2F1-3, NOOA3, and RBL-2; miR-17-5p and miR-20a regulate PACF, RUNX-1, and TGF-R2. Many of these targets are cell cycle regulators, e.g. miR-18a regulates CTFG gene, and miR-19a acts on PTEN and THBS-1. miR-17-5p is efficient decouple negative regulator of MAPK signaling cascade (Figures 5,6 ). The inhibition of miR-20a by antisense oligonucleotide causes increased apoptosis after therapy with doxorubicin. miR-17-92 cluster may promote neovascularization through downregulation of the trombospondin-1 and connective tissue growth factor (69) (70) (71) . In the transgenic mice, the miR-17-92 cluster suppresses expression of the tumor suppressor PTEN gene and the pro-apoptotic Bim gene (Figures 4,5 ). is the most frequent genetic abnormality and very often the sole genetic alteration. Deletion of 13q14 is heterogeneous and composed of multiple subtypes, with deletion of RB or the miR-15a and miR-16-1 ( Figure 5 ). Deletion type Ia is relatively uniform in length and extend breakpoints class to the miR-15a and miR-16-1 (75) . Calin et al. demonstrated for the first time that deletions or downregulation of miR15a and miR16-1 gene are located at chromosome 13q14. Deletions of this locus occur in more than 65% of cases of chronic lymphocytic leukemia, as well as in 50% of mantle cell lymphoma, 16-40% of multiple myelomas, and 60% of prostate cancer (Table 1) (81) . The first 9 nucleotides from 5' of miR-15a and miR-16-1 are complementary to bases 3287 to 3279 on the 3'UTR of BCL2, which encodes a protein that can inhibit apoptosis. These miRNAs control the level of BCL2 in normal cells also but the high expression of the oncogenes lead to CLL (74, 81) . The latest report of Calin's group is about two CLL patients carried a germline C to T mutation of the miR-16-1 precursor, which results in decreased miR-16-1 expression levels. This mutation is associated with a family history of CLL (81) . The aggressive form of CLL is characterized by low expression of miR-29 and miR-181b and high expression levels of Tcl-1 and MCL-1 genes (82). Also, a similar finding is identified in case of splenic marginal zone lymphomas. The expression of miR-143 and miR-145 decreased in CLL (83) .
V-region gene recombination Precusor B-cell lymphomas Post-GC lymphomas

Diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common type of nonHodgkin's lymphoma. This lymphoma is heterogeneous genomic entity. By gene expression and immunochistochemical methods, three distinct subgroups of DLBCL were identified: GCB, ABC and PEL. The first subgroup showed as a germinal center B-cells (GCB) (CD10, BCL6, A-MYB, OGG1), This subgroup showed a frequent translocation t(14;18) involving the BCL2 gene. The second subgroup revealed activated B-cell like (ABC) with t(14;18) and Ig hypermutation. The third subgroup identified as primary mediastinal large B cell lymphoma is characterized by anatomic location, clinical presentation, histological and immunophenotypic features (CD30+, CD20+, CD79a+, Pax 5+, PU.1, OCT-2+). The GCB and ABC have different 5-years survival rates of 70-80% and 30-40%, respectively, when not treated with Rutiximab (84). Aberrations of microRNAs genes are widespread in primary of DLBCL and cell lines (85) . About 95% of tumors and 100% cell lines have one alteration of miRNAs integrity. In 20% of DLBCL cases amplification of 36 microRNA genes and deletion in 10% miRNA genes was found ( Figure  5 ) (86) . The miR-155 encoded by BIC nucleotides 241-262 was originally identified as a transcript derived from an integration site for the avian leucosis virus and found to be overexpressed in B cell lymphomas. Philogenetically conserved regions in BIC have the highest homology in 138 nucleotides section of the gene, which encoding the pri-miRNA for miR-155. Until now, 42 genes have been identified, which correlated inversely with miR-155 expression. Putative target genes for miR-155 are: MWAB, TIPI2DA, HNRPA2B1, PU.1, DCX, ENST00000296490, IDN3, OLFM3, BCROL-1, AP3D1, YPEL5, ENST 00000285951, ENST00000366942, DDIT4, MECP2, JARID2, TBR1, ZIC-3, ISCOL, GAB-2, ATP1A2, POLQ, BC029985 (87) . The miR-155 acts as oncogne, but mechanism of action is unknown. BIC gene activation can accelerate the pathogenesis of lymphomas. The cells of DLBCL have 30-fold increase in copy numbers of miR-155 then normal circulating B cells (88) . The BIC/miR-155 is positive in ~67% diffuse B cell lymphoma cases and primary mediastinal lymphoma. The miR-155 levels were elevated 12 to 60 fold relative to the control B cells in DLBCL. The miR-155 levels in ABC subgroup of DLBCL were two to three folds higher than in GCB-DLBCL subtype. The alterations in miR-155 expression are not absolutely specific for lymphomas ( Figure 5 ). This deregulation is observed and in other solid tumors (29, 88) . Zhang B, Farwely MA, concluded, that miR expression signature which contain three miRNAs (miR-21, miR-155, and miR-221) was highly expressed in ABC subtype then in GCB-DLBCL type of DLBCL and may be used for distinguishing of these two types of DLBCL ( Table 1 ). The expression of miR-21 was an independent prognostic factor in de novo DLBCL but no association between expression levels of miR-155 and miR-221 and DLBCL prognosis was found (89) . The Smad proteins controlled the processing of miR from pri-miR-21 to pre-miR-21. The miR-221 is not a target for c-kit gene. The circulating levels of miR-155 were higher in serum patients with DLBCL compared to healthy control. The high expression of pre -miR-155/ BIC RNA was detected in DLBCL, Burkitt's lymphoma, and other lymphomas (Table 1) (Table 1) (93, 94) . Primary effusion lymphoma (PEL) is a rare DLBCL form, which is caused by Kaposi sarcoma herpes virus (KSHV) and in 80% of cases associated with EBV infection ( Figure 5 ). KSHV encodes 12 microRNAs. The KSHV-miR-K12-11 is an ortolog has miR-155 and may contribute to the development of PEL's cell phenotype, which is a late stage of B cell differentiation (95) . The EBV+ PEL cells and Burkitt's lymphoma cells (BLs) type I expressed only BART2 microRNA. Whereas, DLBCLs cell lines expressed BART2 microRNA and BHRF1-3 microRNAs. This expression inversely correlated with target CXCL-11 1TAC gene (96) . In KSHV, infected lymphoma tumor specific downregulation of miR-155, miR-221, and miR-222 was identified ( The main morphological MCL subgroups are classical MCL and blastoid variant (BV), which constitute about 10% of MCL and is clinically and are more aggressive. In MCL-BV, there is increased number of numerical chromosomal alteration and more frequently losses of tp53 gene (99) . By clustering analysis and principal component analysis of set of 15 miRNAs may differentiate conventional from blastoid form of MCL and progressive disease from non-progresive disese (Table 1) 
Follicular lymphoma
Follicular lymphoma represents ~22% of all cases of non-Hodgkin's lymphomas and is typical indolent but incurable disease. Follicular lymphoma is B cell malignancy and has the tendency to transform into DLBCL, with translocation t(14;18)(q23;q21) in 90% of cases. This translocation leads to the overexpression of BCL2 gene. This transformation may be associated with gene rearrangement of c-myc gene, mutation in p53, mutation in BCL6, or inactivation of p15 or p16 (102) . The t(14;18) translocation in 80-90% of FLs and consecutive overexpression of BCL-2 leads to an accumulation in GCB cells with prolonged life span. A later, during multistep process of lymphomagnesis additional genetic or epigenetic mutation lead to progress of FLs (103) . Globally in low grade FLs significantly reduced expression of 38 microRNAs during transformation was detected. Reducted expression in miRNAs contributes the increase of expression oncogenes and transformation process of FLs in DLBCL (Table 1) . In follicular lymphoma specific aberrant expression of MIRN9/9*, MIRN301, MIRN338, MIRN213 was identified. In addition, the miR-17-92 cluster is amplified in follicular lymphomas, Mantle cell lymphomas and primary cutaneous B cell lymphoma ( Figure 5 ) (77, 93, 103) . Specifical lymphoma form is spleen marginal zone lymphoma (SMZL). In this lymphoma miR-21 is overexpressed ( Figure 5 , In all BL cases, BHRF1-3 miRNA expression inversely correlates with levels of a cellular target CXCL-11/1-TAC (96, 111, 112) . The expression of BIC and miR-155 is not a common finding in BL (Table 1) . However, EBV latency type III infection controls induction of BIC expression in EBV-positive BL cells lines and all posttransplantation lymphoproliferative disorders. In Ramos cell line, which originates from BL, a specific block in maturation of BIC to miR-155 was identified or processing of BIC via unknown mechanism was prevented. Partially reconstructive BIC activation and NF-kB activation cause expression of EBV-LMP1 that lead to immortalization of B lymphocytes (113) (114) (115) . The expression levels of miR-143 and miR-145 were significantly reduced in the EBV transformed B cell lines, BL cell lines, CLL, and B cell lymphomas (Table 1, Figure 5 ). One target gene for miR-143 is ERK5 and for miR-145 are MAP3K3 and MAP4K4, and others. miR-143 and miR-145 may be useful as biomarkers of transformation normal cells to B neoplastic cells (83, 116, 117) . In the clinical practice, the micro RNA expression profiles can be used to distinction between DLBCL and BLs ( Figure 5 ).
T-cell lymphomas
The T cell lymphomas represent heterogeneous subgroups of non-Hodgkin's lymphomas. In these lymphomas role and function of microRNAs is at the beginning of research. In experimental model of T-cell lymphomas, caused by strain SL3-3 of murine leukemia virus (MLV), overexpression of the mmumiR-1204 and miR-106a was identified (109, 118) . Also, Marek Disease Virus (MDV), which causes avian T cell lymphoma, play important role through expression of microRNA (118) . In a peripheral T-cell lymphoma that is consistent with a type II latency EBV infection specific expression of miR-143 and miR-145 was identified (Table 1 ) (119). through an intracellular gene silencing mechanism, namely RNA interference. miRNAs are specific and important components differentiation of lymphocytes. The research of miRNAs alterations and cancer and lymphomas may lead to establishment of novel methods for precisely subclassifying some lymphomas based on miRNAs profiles. The combining miRomics, genomics, and proteomics might help delineating spectrum of targets that are regulated by miRNAs. Also, miRNAs may be used as a specific molecular marker for the stratification of prognostic subgroups of lymphomas. microRNAs are relatively resistant to RNase degradation and because of that useful for early detection, diagnosis and follow-up using biological fluids of lymphoma patients. In future, it is necessary to continue work on determination of microRNA in stem cell maintenance, embryonic development, tissue differentiation, adult physiology, disease pathology, cancer research, and viral infection. microRNAs are small molecules, may modulate multiple oncogenic pathways in cell, and may serve as potential effective targets for antitumor therapy. Nowadays, attention has been focused on study of antisense oligonucleotide to inhibit mRNA function.
CONCLUSION AND PERSPECTIVES
